Načítá se...
Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer
Although selective metabolic and receptor-based molecular agents will surely be included in the future of prostate cancer diagnosis and therapy, currently available inorganic compounds—such as (18)F-NaF for the diagnosis of bony disease and (223)RaCl(2) for the therapy of bone metastases—were recent...
Uloženo v:
| Vydáno v: | J Nucl Med |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Society of Nuclear Medicine
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5093914/ https://ncbi.nlm.nih.gov/pubmed/27694165 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.115.170746 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|